AIM Rule 26
The following information is disclosed in accordance with AIM Rule 26
|Registered name:||Summit Therapeutics plc|
|Country of incorporation:||England & Wales|
|Main country of operation:||United Kingdom|
|Registered address:||136a Eastern Avenue Milton Park Abingdon Oxfordshire OX14 4SB United Kingdom|
|Company Secretary:||Melissa Strange, FCCA|
Summit Therapeutics plc is subject to the UK City Code on Takeovers and Mergers.
The Company’s current articles of association can be viewed here:
The Company’s Admission Document to AIM, a market of the London Stock Exchange is available:
Please note this document was issued more than twelve years ago and is accordingly substantially
out of date. For more accurate and up-to-date information, please refer to other sections of this website, the latest Annual Report, our filings with the US Securities & Exchange Commission, recent regulatory announcements and other such information
sources on the web.
Click here for more information about the board of directors. Click here for more information about the responsibilities of the directors and any committees.
Click here for more information about number of securities in issue and, insofar as the company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.
Click here for access to the Company’s Annual and Interim Reports.
Click here for details of the Company’s advisers.
This section of the website, and the information that can be accessed from this page, was last updated to comply with AIM Rule 26 on: 30 April 2018